One adult in ten will have diabetes by 2030

World Diabetes Day 2011 marks the release of the International Diabetes Federation's 5th edition of the Diabetes Atlas. New figures indicate that the number of people living with diabetes is expected to rise from 366 million in 2011 to 552 million by 2030, if no urgent action is taken. This equates to approximately three new cases every ten seconds or almost ten million per year. IDF also estimates that as many as 183 million people are unaware that they have diabetes.

In some of the poorest regions in the world such as Africa, where infectious diseases have traditionally been the focus of health care systems, diabetes cases are expected to increase by 90% by 2030. At least 78% of people in Africa are undiagnosed and do not know they are living with diabetes.

Other figures to be released today also show:

  • 80% of people with diabetes live in low and middle income countries.
  • 78,000 children develop type 1 diabetes every year
  • The greatest number of people with diabetes are between 40-59 years of age

"In every country and in every community worldwide, we are losing the battle against this cruel and deadly disease" said Jean Claude Mbanya, President of the International Diabetes Federation (IDF) "We want World Diabetes Day 2011 to bring these alarming diabetes facts into the global spotlight. We demand that public and world leaders act on diabetes now."

The release of these figures follow the September meeting of 193 Heads of State and government at the UN High Level Meeting in New York to agree on a Political Declaration on Non-Communicable Diseases (NCDs) including diabetes. This marks a major milestone for diabetes and other NCDs. However in some areas stronger commitments are needed.

"World leaders have recognised the magnitude and impact of these diseases and the urgent need for action. In some key areas we wanted stronger commitments and targets but the Declaration will accelerate international progress on diabetes and NCDs, saving millions of people from preventable death and disability" said Ann Keeling, CEO, International Diabetes Federation (IDF) and Chair of the NCD Alliance.

IDF is committed to translating UN Commitments into action by fostering a new level of partnership involving public, private and people.

It is hoped that campaigns such as today's World Diabetes Day will continue to raise the voice of people with diabetes and move from advocacy to action on a global scale.

For more information on the 5th edition Diabetes Atlas and country-by-country statistics visit: http://www.idf.org/diabetesatlas (online as of 14 November).

About World Diabetes Day
World Diabetes Day (WDD) is celebrated every year on November 14. The World Diabetes Day campaign is led by the International Diabetes Federation (IDF) and its member associations. It engages millions of people worldwide in diabetes advocacy and awareness. World Diabetes Day was created in 1991 by the International Diabetes Federation and the World Health Organization in response to growing concerns about the escalating health threat that diabetes now poses. World Diabetes Day became an official United Nations Day in 2007 with the passage of United Nation Resolution 61/225. The campaign draws attention to issues of paramount importance to the diabetes world and keeps diabetes firmly in the public spotlight.

About the International Diabetes Federation (IDF)
The International Diabetes Federation (IDF) is an umbrella organisation of over 200 national diabetes associations in over 160 countries. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 1950. IDF's mission is to promote diabetes care, prevention and a cure worldwide.

Most Popular Now

AstraZeneca takes next steps towards broad and equ…

AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements ...

Johnson & Johnson announces acceleration of it…

Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Calquence showed promising clinical improvement in…

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved cl...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

New consortium EUbOPEN will provide tools to unloc…

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to bet...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Mayo finds convalescent plasma safe for diverse pa…

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findi...